HEXO Corp. logo
HEXO Corp. HEXO

Annual report 2022
added 12-23-2023

report update icon

HEXO Corp. Balance Sheet 2011-2025 | HEXO

Annual Balance Sheet HEXO Corp.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -150 M -83.3 M -39.3 M -17.9 M -809 K -922 K -475 K - - -

Long Term Debt

- - 29 M 30.3 M - 20.6 M - - - - - -

Long Term Debt Current

914 K 1.73 M 4.77 M - - - - - - - - -

Total Non Current Liabilities

- - - 38.2 M - 20.6 M - - - - - -

Total Liabilities

367 M 580 M 136 M 89.9 M 12.1 M 23.7 M 11.6 K 44 K 21.5 K - - -

Deferred Revenue

- - 8.21 M - - - - - - - - -

Retained Earnings

- - -659 M -52.3 M -30.5 M -16.1 M -323 K -245 K -29.3 K - - -

Total Assets

681 M 1.31 B 693 M 879 M 335 M 56.2 M 812 K 922 K 492 K - - -

Cash and Cash Equivalents

83.2 M 67.5 M 184 M 114 M 99 M 38.5 M - - - - - -

Book Value

314 M 732 M 557 M 789 M 323 M 32.5 M 800 K 878 K 471 K - - -

Total Shareholders Equity

- - 557 M 777 M 323 M 32.4 M - - - - - -

All numbers in CAD currency

Quarterly Balance Sheet HEXO Corp.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - 42.2 M - - - 24.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - 580 M - - - 136 M - - - 89.9 M - - - 12.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - -774 M - - - -659 M - - - -113 M - - - -43.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - - - 1.31 B - - - 693 M - - - 879 M - - - 335 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - 67.5 M - - - 184 M - - - 114 M - - - 99 M - - - 38.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - - - 732 M - - - 557 M - - - 789 M - - - 323 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - - - 732 M - - - 557 M - - - 789 M - - - 323 M - - - 32.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CAD currency

Balance Sheet is a fundamental financial report of HEXO Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
$ 0.74 -3.53 % $ 52.6 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.69 -3.13 % $ 182 M canadaCanada
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.06 -6.57 % $ 1.61 B canadaCanada
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 5.18 -4.17 % $ 86.3 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Emergent BioSolutions Emergent BioSolutions
EBS
$ 11.76 2.98 % $ 602 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
$ 10.97 0.18 % $ 36.7 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
$ 21.39 0.14 % $ 2.04 B franceFrance
Evolus Evolus
EOLS
$ 7.17 1.85 % $ 445 M usaUSA
Harrow Health Harrow Health
HROW
$ 46.47 -1.25 % $ 1.52 B usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.55 -0.64 % $ 27.1 M chinaChina
Bausch Health Companies Bausch Health Companies
BHC
$ 6.83 -1.37 % $ 2.49 B canadaCanada
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 4.86 0.73 % $ 640 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.82 -5.36 % $ 402 M canadaCanada
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 3.03 19.57 % $ 42.6 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.71 1.6 % $ 1.24 B usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 0.88 -5.09 % $ 20.5 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 5.81 -1.02 % $ 237 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 3.45 -3.96 % $ 4.28 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.32 6.4 % $ 130 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 12.85 -2.17 % $ 1.77 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
$ 0.11 -2.7 % $ 1.74 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 2.02 -8.68 % $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Veru Veru
VERU
$ 2.43 0.41 % $ 328 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
cbdMD cbdMD
YCBD
$ 1.4 14.75 % $ 6.04 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 0.64 -1.21 % $ 30.6 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 11.41 -6.09 % $ 7.05 B canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.69 -3.43 % $ 17.6 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Viatris Viatris
VTRS
$ 11.68 0.21 % $ 14.2 B usaUSA